Controversies in Thyroid Pathology: the Diagnosis of Follicular Neoplasms

Overview

Journal Endocr Pathol

Specialties Endocrinology
Pathology

Date 2008 Jun 13

PMID 18548351

Citations 11

Authors

Stefano Serra

Sylvia L Asa

Affiliations

Soon will be listed here.

Abstract

Thyroid nodules are common; almost 20% of the population has a palpable thyroid nodule and approximately 70% has a nodule detected by ultrasound. Thyroid cancer is the most frequent endocrine malignancy, and incidence rates have steadily increased over the last decades. Papillary carcinoma (PTC) is the most common malignant neoplasm of the thyroid; the diagnosis of this most frequent type (85-90%) has been increasing, possibly due to changing recognition of morphologic criteria. PTC is defined histologically as a malignant tumor showing evidence of follicular epithelial differentiation and characterized by distinctive nuclear features. However, there are borderline lesions that do not completely fulfill these criteria, making the diagnosis difficult. The use of immunohistochemical and molecular markers adds objective criteria to this confusing and controversial area of pathology. We review the differential diagnosis of well-differentiated follicular thyroid neoplasms and the ancillary techniques and molecular characteristics that have been proposed for application in the diagnosis of PTC.

Citing Articles

A glance at the actual role of glutamine metabolism in thyroid tumorigenesis.

Abooshahab R, Hooshmand K, Razavi F, Dass C, Hedayati M EXCLI J. 2021; 20:1170-1183.

PMID: 34345235 PMC: 8326501. DOI: 10.17179/excli2021-3826.

Advances in metabolomics of thyroid cancer diagnosis and metabolic regulation.

Abooshahab R, Gholami M, Sanoie M, Azizi F, Hedayati M Endocrine. 2019; 65(1):1-14.

PMID: 30937722 DOI: 10.1007/s12020-019-01904-1.

Immunohistochemical Biomarkers in Thyroid Pathology.

Baloch Z, Mete O, Asa S Endocr Pathol. 2018; 29(2):91-112.

PMID: 29744727 DOI: 10.1007/s12022-018-9532-9.

Serum and urine H NMR-based metabolomics in the diagnosis of selected thyroid diseases.

Wojtowicz W, Zabek A, Deja S, Dawiskiba T, Pawelka D, Glod M Sci Rep. 2017; 7(1):9108.

PMID: 28831094 PMC: 5567318. DOI: 10.1038/s41598-017-09203-3.

Follicular adenomas exhibit a unique metabolic profile. ¹H NMR studies of thyroid lesions.

Deja S, Dawiskiba T, Balcerzak W, Orczyk-Pawilowicz M, Glod M, Pawelka D PLoS One. 2013; 8(12):e84637.

PMID: 24376829 PMC: 3871661. DOI: 10.1371/journal.pone.0084637.

References

Maxwell E, Palme C, Freeman J . Hürthle cell tumors: applying molecular markers to define a new management algorithm. Arch Otolaryngol Head Neck Surg. 2006; 132(1):54-8. DOI: 10.1001/archotol.132.1.54. View

Liu W, Wei W, Winer D, Bamberger A, Bamberger C, Wagener C . CEACAM1 impedes thyroid cancer growth but promotes invasiveness: a putative mechanism for early metastases. Oncogene. 2006; 26(19):2747-58. DOI: 10.1038/sj.onc.1210077. View

Nakamura T, Yana I, Kobayashi T, Shin E, Karakawa K, Fujita S . p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas. Jpn J Cancer Res. 1992; 83(12):1293-8. PMC: 5918745. DOI: 10.1111/j.1349-7006.1992.tb02761.x. View

Nikiforov Y, Rowland J, Bove K, Fagin J . Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res. 1997; 57(9):1690-4. View

Mai K, Bokhary R, Yazdi H, Thomas J, Commons A . Reduced HBME-1 immunoreactivity of papillary thyroid carcinoma and papillary thyroid carcinoma-related neoplastic lesions with Hürthle cell and/or apocrine-like changes. Histopathology. 2002; 40(2):133-42. DOI: 10.1046/j.1365-2559.2002.01315.x. View

Parma J, Duprez L, Van Sande J, Hermans J, Rocmans P, Van Vliet G . Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenomas. J Clin Endocrinol Metab. 1997; 82(8):2695-701. DOI: 10.1210/jcem.82.8.4144. View

Cheung C, Ezzat S, Ramyar L, Freeman J, Asa S . Molecular basis off hurthle cell papillary thyroid carcinoma. J Clin Endocrinol Metab. 2000; 85(2):878-82. DOI: 10.1210/jcem.85.2.6404. View

DAILEY M, Lindsay S, SKAHEN R . Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. AMA Arch Surg. 1955; 70(2):291-7. DOI: 10.1001/archsurg.1955.01270080137023. View

Lloyd R, Erickson L, Casey M, Lam K, Lohse C, Asa S . Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol. 2004; 28(10):1336-40. DOI: 10.1097/01.pas.0000135519.34847.f6. View

10.

Fusco A, Chiappetta G, Hui P, Garcia-Rostan G, Golden L, Kinder B . Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer. Am J Pathol. 2002; 160(6):2157-67. PMC: 1850819. DOI: 10.1016/S0002-9440(10)61164-9. View

11.

Ito Y, Yoshida H, Tomoda C, Miya A, Kobayashi K, Matsuzuka F . HBME-1 expression in follicular tumor of the thyroid: an investigation of whether it can be used as a marker to diagnose follicular carcinoma. Anticancer Res. 2005; 25(1A):179-82. View

12.

Prasad M, Pellegata N, Huang Y, Nagaraja H, de la Chapelle A, Kloos R . Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol. 2004; 18(1):48-57. DOI: 10.1038/modpathol.3800235. View

13.

Apel R, Ezzat S, BAPAT B, Pan N, Livolsi V, Asa S . Clonality of thyroid nodules in sporadic goiter. Diagn Mol Pathol. 1995; 4(2):113-21. DOI: 10.1097/00019606-199506000-00007. View

14.

Harness J, Thompson N, McLeod M, Eckhauser F, Lloyd R . Follicular carcinoma of the thyroid gland: trends and treatment. Surgery. 1984; 96(6):972-80. View

15.

de Matos P, Ferreira A, de Oliveira Facuri F, Assumpcao L, Metze K, Ward L . Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology. 2005; 47(4):391-401. DOI: 10.1111/j.1365-2559.2005.02221.x. View

16.

Hunt J, Tometsko M, LiVolsi V, Swalsky P, Finkelstein S, Barnes E . Molecular evidence of anaplastic transformation in coexisting well-differentiated and anaplastic carcinomas of the thyroid. Am J Surg Pathol. 2003; 27(12):1559-64. DOI: 10.1097/00000478-200312000-00009. View

17.

Schmid K, Farid N . How to define follicular thyroid carcinoma?. Virchows Arch. 2006; 448(4):385-93. DOI: 10.1007/s00428-006-0162-0. View

18.

Cvejic D, Savin S, Petrovic I, Paunovic I, Tatic S, Krgovic K . Galectin-3 expression in papillary microcarcinoma of the thyroid. Histopathology. 2005; 47(2):209-14. DOI: 10.1111/j.1365-2559.2005.02199.x. View

19.

Yamashina M . Follicular neoplasms of the thyroid. Total circumferential evaluation of the fibrous capsule. Am J Surg Pathol. 1992; 16(4):392-400. DOI: 10.1097/00000478-199204000-00008. View

20.

Adeniran A, Zhu Z, Gandhi M, Steward D, Fidler J, Giordano T . Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol. 2006; 30(2):216-22. DOI: 10.1097/01.pas.0000176432.73455.1b. View